Evidence map›Paper›PMID 29614442›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2018

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

Terri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, Stan B Kaye, Udai Banerji, Juanita S Lopez, Johann de Bono, Winette T A van der Graaf, Angela J George

Open access · bronzeAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Terri Patricia McVeighCancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK. Electronic address: terri.mcveigh@gmail.com.
Raghav SundarDrug Development Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK; Department of Haematology-Oncology, National University Health System, Singapore.
Nikolaos DiamantisDrug Development Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.
Stan B KayeDrug Development Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.
Udai BanerjiDrug Development Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.
Juanita S LopezDrug Development Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.
Johann de BonoDrug Development Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.
Winette T A van der GraafSarcoma Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.
Angela J GeorgeCancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK; Gynaecology Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.
Royal Marsden NHS Foundation Trust · GB

Funding

Cancer Research UK 11566Cancer Research UK 22897Cancer Research UK A15573
6 · The paper itself

Abstract

introductionAdolescents and young adults (AYAs) diagnosed with cancer between ages 15-39 years may harbour germline variants associated with cancer predisposition. Such variants represent putative therapeutic targets, as may somatic variants in the tumour. Germline and tumour molecular profiling is increasingly utilised to facilitate personalisation of cancer treatment in such individuals.

aimConsidering AYAs with advanced solid tumours managed in a specialist drug development unit (DDU), the aims of this study were to investigate the use and impact of: 1. Germline genetic assessment. 2. Tumour molecular profiling.

methodsAYAs treated in the DDU at the Royal Marsden Hospital between 2002 and 2016 were identified from departmental databases. Data regarding clinicopathological features, clinical assessments and germline and tumour genetic testing were retrieved by chart review.

resultsThe study cohort included 219 AYAs. Common cancer types included sarcoma (41, 19%); cervical (27, 12%); breast (25, 11%); ovarian (23, 11%) and colorectal (21, 10%) cancers. Germline testing was undertaken in 34 (16%) patients, 22 of whom carried a pathogenic variant. Using current testing criteria, an additional 32 (15%) would be eligible for germline testing based on their personal history of cancer alone. Tumour testing was undertaken in 46 (21%) individuals. Somatic mutations were commonly identified in TP53 13 (28%); PIK3CA (8, 18%); KRAS (4, 9%) and MET 5 (11%). DISCUSSION: A significant proportion of AYAs with advanced cancer have targetable somatic or germline mutations. Consideration of familial risk factors and inclusion of germline testing wherever appropriate can complement tumour testing to optimise patient management and inform management of at-risk relatives.

Indexed as

Gene Expression ProfilingAdolescentAdultClinical Trials, Phase I as TopicDisease ProgressionFemaleGenetic Predisposition to DiseaseGenetic TestingGerm-Line MutationHumansMaleMonitoring, PhysiologicNeoplasmsNeoplasm StagingPrognosisYoung AdultAdolescent and young adultAYAGenomic profilingPersonalised medicinePhase 1 trial

Identifiers

PMID29614442
PMCPMC6296443
OpenAlexW2795230491

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.